| Authors: |
Kim GM; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea., Kim S; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea.; Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Republic of Korea., Lee MA; Division of Medical Oncology, Seoul St, Mary's Hospital, The catholic University of Korea, Seoul, Korea., Byun MS; Genexine, Inc., Seoul, Korea., Choi D; NeoImmuneTech, Inc., Rockville, MD, USA., Yang SH; NeoImmuneTech, Inc., Rockville, MD, USA., Woo J; Genexine, Inc., Seoul, Korea., Sung YC; Genexine, Inc., Seoul, Korea., Shin EC; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea., Park SH; Graduate School of Medical Science and Engineering, Korea Advanced Institute of Science and Technology, Daejeon, Korea. park3@kaist.ac.kr., Kim TW; Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea. twkimmd@amc.seoul.kr., Sohn J; Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea. ONCOSOHN@yuhs.ac. |
